STAT+: Biden invokes Cold War-era law to stem drug shortages
WASHINGTON — President Biden is using a Cold War-era law to stem drug shortages by…
Category: STAT+
STAT+: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma
The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which…
STAT+: Vertex pushes a donation program to widen access to cystic fibrosis treatments, but advocates say it’s not enough
Vertex Pharmaceuticals is being accused by a group of advocates and physicians of refusing to…
STAT+: Mayo Clinic to spend $5 billion on tech-heavy redesign of its Minnesota campus
Mayo Clinic will spend $5 billion to reinvent its flagship medical campus in Rochester, Minn.,…
STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages
Top of the morning to you, and a fine one it is. Cool breezes and…
STAT+: Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans
Belgium drugmaker Argenx said Tuesday that its antibody medicine failed to achieve the goals of…
STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs
In response to strained budgets, a growing number of state and local governments across the…
STAT+: Springworks wins FDA approval for drug to treat desmoid tumors
The Food and Drug Administration on Monday approved the first treatment for people with desmoid…
STAT+: Most clinical trials run in Canada failed to take basic steps toward transparency, analysis finds
Just 3% of more than 3,700 studies run exclusively in Canada over a recent 10-year…
STAT+: Pharmalittle: Bioscience job market is upside down; Sanofi and Regeneron’s blockbuster Dupixent may find bigger market
Good morning, everyone, and nice to see you again after an extended break on this…
STAT+: Sales of antibiotics for food-producing animals dropped by more than half in Europe over the past decade
Amid concerns over the use of medically important antibiotics given to food-producing livestock, sales of…
STAT+: With biotech in a slump, the industry’s job market is upside down
After earning her doctorate in cell biology at the University of Pennsylvania in June, Sierra…
.jpg)
STAT+: With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market
LONDON — The inflammation-targeting therapy Dupixent succeeded in a Phase 3 trial in patients with…
STAT+: Antitrust lawsuit alleges UnitedHealth’s Optum pressured a California hospital to stop competing over physicians
UnitedHealth Group’s Optum division is already the largest employer of physicians in the United States,…
STAT+: U.S. Anesthesia Partners, Welsh Carson face class action over monopoly allegations
Union health plans that represent electricians and plumbers in Texas have filed a class action…
STAT+: Evelo Biosciences, a microbiome company launched by Flagship, shuts down
Evelo Biosciences, a startup hoping to use the trillions of microbes in and on the…
Pharmalittle: European patent agency invalidates a Moderna mRNA patent; pharma ally Eshoo plans to retire
Good morning! This is Jonathan Wosen, West Coast biotech and life sciences reporter, filling in…
STAT+: Health tech startups warn that overregulating AI could hamper innovation
Entrepreneurs across the country desperate to bring the power of AI into health care are…
STAT+: House Republicans call CDC director to testify
WASHINGTON — A House committee that has sparred with the Biden administration over its handling…
STAT+: Prominent pharmaceutical industry ally Anna Eshoo to retire
WASHINGTON — Rep. Anna Eshoo, one of the House of Representatives’ top Democrats on health…
STAT+: Sen. Bernie Sanders publicly pressures Merck, J&J, and Bristol Myers Squibb to testify on drug pricing
WASHINGTON — Senate Democrats, led by Sen. Bernie Sanders (I-Vt.) on Tuesday mounted a public…
STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup
Hello, everyone. Damian Garde here, filling in for Ed Silverman on what is an abbreviated…
STAT+: Flagship Pioneering launches Quotient, a new biotech, in two countries
Flagship Pioneering, the venture capital firm behind Moderna, on Tuesday unveiled a new biotech called…
STAT+: Mixed study results for MorphoSys blood-cancer drug raise questions about approval
LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a…
STAT+: How the CEO of the largest medical device accelerator molds medtech startups
If Paul Grand weren’t the CEO of MedTech Innovator, the largest medical device accelerator in…
STAT+: Delay of eye drop recall highlights FDA’s impotence on the issue
WASHINGTON — It took nearly three weeks for a maker of eye drops to recall…
STAT+: Pharmalittle: CRISPR pioneers reflect on future of gene editing; U.K. and pharma reach deal on how NHS pays for drugs
Good morning and welcome to Thanksgiving week! STAT reporter Andrew Joseph here filling in for…
STAT+: U.K., pharma industry strike deal for how the NHS pays for medicines
LONDON — The U.K. and the pharmaceutical industry have reached a deal on a five-year…
STAT+: What Eli Lilly’s Zepbound reveals about the intricate process of naming drugs today
Whether you’re a fan of the drug name Zepbound or, like one X user, think…
STAT+: How a major hospital shows just how inflated hospital list prices are
Hospitals’ list prices for surgeries, therapies, and other procedures always come with massive discounts. Financial…
.jpg)
STAT+: Hospitals put tech spending on a tight leash, raise the bar for pilots
Health systems whose budgets were squeezed dry during the pandemic are creeping back into the…
STAT+: CRISPR’s pioneers reflect on the first gene-editing treatment
The revolution started in silence. Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first…
STAT+: FDA approves Medtronic high blood pressure device despite a negative advisory panel vote
The Food and Drug Administration has approved a Medtronic device to lower blood pressure, the…
STAT+: Biden appoints Vanderbilt oncologist to head National Cancer Institute
WASHINGTON — President Biden on Friday said he plans to appoint cancer researcher and doctor…
STAT+: A digital pill shows early promise in detecting opioid overdose, sleep apnea
Gathering health data remotely is a pain. Forgetting to slip on a wearable is easy,…
STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs
And so, another working week will soon draw to a close Not a moment too…
STAT+: Even as Wegovy rides high, interest surges in weight loss drugs that preserve muscle
Have you ever seen a mouse with a set of muscles more appropriate for a…
STAT+: Doctors divide over reforming a secretive panel that determines their Medicare pay
WASHINGTON — Doctors are splitting, specialty by specialty, over whether and how to overhaul a…
STAT+: FDA’s Janet Woodcock to retire early next year
WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the…
STAT+: FDA cites Dr. Reddy’s for quality control problems at a biologics plant
Dr. Reddy’s Laboratories, one of the world’s largest generic drugmakers, was cited by the U.S….
STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Bristol wins U.S. approval for lung cancer drug targeting rare genetic mutation
The Food and Drug Administration on Wednesday approved a new treatment for people with non-small…
STAT+: U.K. approves world’s first CRISPR-based medicine, giving greenlight to therapy for sickle cell, thalassemia
LONDON — Regulators in the U.K. on Thursday approved a CRISPR-based medicine to treat both…
STAT+: After four patients died of gene therapy, Astellas sees possible explanation — and a way forward
A gene therapy study, halted when four children with a rare neuromuscular disorder died after…
STAT+: House panel passes PBM reforms, ratcheting up chance for passage
WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug…
STAT+: More drug and device patents were invalidated for bad info than those filed by other industries, analysis finds
The patents on medicines and devices approved by the U.S. Food and Drug Administration were…
STAT+: FDA’s latest reorganization puts a new emphasis on its investigations
WASHINGTON — There’s about to be a new acronym in town. The Food and Drug…
STAT+: House moves to limit so-called gain-of-function research
WASHINGTON — House lawmakers late Tuesday voted to attach a U.S. ban on controversial infectious…
STAT+: Pharmalittle: German regulator eyes Ozempic export ban amid shortages; NIH-funded clinical trials lagging pharma’s in enrollment
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says
WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for…